Table 1.

AEs by category and individual events with ≥2 subjects in any group (all‐subjects population)

	GSK2330811
	Placebo N = 10	0.1 mg kg–1 N = 6	0.3 mg kg–1 N = 6	1 mg kg–1 N = 6	3 mg kg–1 N = 6	6 mg kg–1 N = 6
Any AE, n (%)	10 (100)	6 (100)	5 (83)	5 (83)	6 (100)	6 (100)
Infections and infestations, n (%)	7 (70)	1 (17)	4 (67)	2 (33)	1 (17)	3 (50)
Nasopharyngitis	6 (60)	0 (0)	2 (33)	2 (33)	1 (17)	1 (17)
Folliculitis	0 (0)	0 (0)	2 (33)	0 (0)	0 (0)	0 (0)
Nervous system disorders, n (%)	3 (30)	2 (33)	1 (17)	0 (0)	3 (50)	5 (83)
Headache	3 (30)	2 (33)	1 (17)	0 (0)	2 (33)	2 (33)
Sinus headache	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (33)
Injury, poisoning and procedural complications, n (%)	3 (30)	4 (67)	1 (17)	2 (33)	0 (0)	1 (17)
Scratch	0 (0)	2 (33)	0 (0)	0 (0)	0 (0)	0 (0)
Soft tissue injury	0 (0)	2 (33)	0 (0)	0 (0)	0 (0)	0 (0)
Respiratory, thoracic and mediastinal disorders, n (%)	0 (0)	1 (17)	1 (17)	1 (17)	4 (67)	2 (33)
Oropharyngeal pain	0 (0)	0 (0)	0 (0)	0 (0)	2 (33)	2 (33)
Skin and subcutaneous tissue disorders, n (%)	3 (30)	1 (17)	0 (0)	1 (17)	2 (33)	1 (17)
Dermatitis contact	3 (30)	0 (0)	0 (0)	1 (17)	0 (0)	0 (0)
Gastrointestinal disorders, n (%)	2 (20)	1 (17)	1 (17)	0 (0)	1 (17)	1 (17)
General disorders and administration site conditions, n (%)	1 (10)	1 (17)	1 (17)	1 (17)	0 (0)	2 (33)
Musculoskeletal and connective tissue disorders, n (%)	3 (30)	0 (0)	0 (0)	0 (0)	0 (0)	3 (50)

AE, adverse event.